Document is current
Any future updates will be listed below
-
Authors
Li, Lian
Xu, Liangliang
Zhou, Siqi
Wang, Peng
Zhang, Ming https://orcid.org/0000-0002-8276-691X
Li, Bo
-
Clinical Trials BETA
Clinical trials referenced in this document:
chictr2100052407 at Chinese Clinical Trial RegistryDocuments that mention this clinical trial
Tumour site is a risk factor for hepatocellular carcinoma after hepatectomy: a 1:2 propensity score matching analysis
https://doi.org/10.1186/s12893-022-01564-5
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (71673193)
Key research and development project of science and technology department of Sichuan Province (2021YFS0106)
- License Information
-
More Information
Article History
Received: 18 November 2021
Accepted: 15 March 2022
First Online: 21 March 2022
Declarations
:
: We confirm that all methods were performed in accordance declaration of Helsinki with the relevant guidelines and regulations and our research has been approved by the West China Hospital of Sichuan University Biomedical Research Ethics Committee. In this retrospective study, verbal consent has been obtained from study participants and application form for exemption of informed consent has been approved by the West China Hospital of Sichuan University Biomedical Research Ethics Committee.
: Not applicable.
: The authors declare that they have no competing interests.
